Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6042 followers
Created: 2025-07-22 07:18:05 UTC

Blue Jet Healthcare Q1 2025 Results: Revenue Up, Profits Dip 📊 | MCap XXXXXXXXX Cr

- Revenue from operations: ₹3,547.58M (Q1 2025) vs. ₹3,404.45M (Q4 2024)
- Total income: ₹3,630.12M (other income: ₹82.54M)
- Profit before tax (PBT): ₹1,228.60M (down from ₹1,472.12M in Q4 2024)
- Net profit: ₹911.70M (vs. ₹1,100.95M in Q4 2024)
- EPS: ₹5.26 (basic and diluted)
- Core business: Manufactures artificial sweeteners, contrast media intermediates, pharma intermediates, and APIs
- No subsidiaries, associates, or joint ventures as of June 30, 2025

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

![](https://pbs.twimg.com/media/GwccYilbwAAVoU6.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947556739794276519/c:line.svg)

**Related Topics**
[eps](/topic/eps)
[tax bracket](/topic/tax-bracket)
[mcap](/topic/mcap)
[coins healthcare](/topic/coins-healthcare)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1947556739794276519)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Investor_Feed Avatar Investor Feed @Investor_Feed on x 6042 followers Created: 2025-07-22 07:18:05 UTC

Blue Jet Healthcare Q1 2025 Results: Revenue Up, Profits Dip 📊 | MCap XXXXXXXXX Cr

  • Revenue from operations: ₹3,547.58M (Q1 2025) vs. ₹3,404.45M (Q4 2024)
  • Total income: ₹3,630.12M (other income: ₹82.54M)
  • Profit before tax (PBT): ₹1,228.60M (down from ₹1,472.12M in Q4 2024)
  • Net profit: ₹911.70M (vs. ₹1,100.95M in Q4 2024)
  • EPS: ₹5.26 (basic and diluted)
  • Core business: Manufactures artificial sweeteners, contrast media intermediates, pharma intermediates, and APIs
  • No subsidiaries, associates, or joint ventures as of June 30, 2025

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

XXX engagements

Engagements Line Chart

Related Topics eps tax bracket mcap coins healthcare investment

Post Link

post/tweet::1947556739794276519
/post/tweet::1947556739794276519